A small-molecule CNTF analog that promotes neurogenesis and reduces tau pathology — studied for Alzheimer's prevention.
P21 (also written P021) is an 11-amino acid peptide derived from ciliary neurotrophic factor (CNTF) — a neurotrophic factor that supports neuronal survival, differentiation, and neurite outgrowth. Unlike full-length CNTF (which requires injection and has systemic side effects including weight loss), P21 is a small, modified peptide that can cross the blood-brain barrier and be administered intranasally.
P21 works by inhibiting leukemia inhibitory factor (LIF) receptor signaling and increasing BDNF levels in the brain. In Alzheimer's models, it has been shown to reduce tau hyperphosphorylation (a hallmark of the disease), increase neurogenesis in the hippocampus, and improve cognitive function.
Developed by Khalid Iqbal's group at the New York State Institute for Basic Research in Developmental Disabilities, P21 represents a novel approach to neurodegenerative disease prevention — targeting neurogenesis and tau pathology simultaneously.
Animal studies demonstrate P21 promotes dentate gyrus neurogenesis (new neuron formation in the memory center), reduces tau pathology, and reverses cognitive deficits in Alzheimer's mouse models. Chronic oral or intranasal administration prevented cognitive decline in aging models.
The mechanism is particularly interesting: P21 increases BDNF expression while decreasing tau phosphorylation through modulation of GSK-3β activity. This dual action addresses both the neurodegeneration and the protein aggregation aspects of Alzheimer's pathology.
📚 Key Reference: PMID: 24573978 (P21 neurogenesis and tau)
Limited human data. Animal studies show no significant toxicity. Weight loss (a side effect of full-length CNTF) is not observed with P21 at effective doses. Consult your provider.
NOT FDA-approved. Research use only. Published in peer-reviewed journals but no clinical trials.